Title

Earning Preview: Pharming Group N.V. this quarter’s revenue is expected to increase by 30.28%, and institutional views are bullish

Abstract

Pharming Group N.V. will release its quarterly results on March 12, 2026, Pre-Market, with expectations centered on accelerating revenue growth, robust margins, and disciplined operating spending following upbeat full-year indications and recent regulatory developments.

Market Forecast

Consensus expectations for Pharming Group N.V.’s current quarter point to total revenue of $105.19 million, a year-over-year increase of 30.28%, alongside adjusted EPS estimated at $0.008, implying 24.89% growth, and EBIT of $12.85 million, implying 137.96% growth. Margin forecasts are not explicitly provided for the quarter, though last quarter’s gross profit margin of 92.73% and net profit margin of 7.76% offer a clear baseline for profitability dynamics. The company’s commercial portfolio is expected to sustain revenue momentum into the quarter amid ongoing patient demand and a disciplined approach to operating expenses. The most promising growth contributor remains the recently launched immunology therapy franchise; while the segment’s revenue was not reported separately, last quarter’s total revenue was $97.30 million with 30.00% year-over-year growth, indicating healthy contribution from newer assets within the overall mix.

Last Quarter Review

Pharming Group N.V. delivered last quarter revenue of $97.30 million, a 30.00% year-over-year increase, with a gross profit margin of 92.73%, GAAP net profit attributable to the parent of $7.55 million, a net profit margin of 7.76%, and adjusted EPS of $0.01, up 600% year-over-year. A key highlight was the significant operating outperformance, with EBIT of $15.80 million versus a prior estimate of -$6.90 million, marking a positive surprise of $22.70 million and reflecting tight spending and strong revenue conversion. Main business performance was characterized by stable commercial demand across the portfolio, with total revenue reaching $97.30 million and growing 30.00% year-over-year, while quarter-on-quarter net profit growth registered at 60.80%.

Current Quarter Outlook (with major analytical insights)

Commercial Portfolio Trajectory

Pharming Group N.V.’s commercial portfolio is positioned to extend the momentum observed in the prior quarter, with the market tracking a revenue estimate of $105.19 million and adjusted EPS of $0.008 for the current period. The prior quarter’s 92.73% gross profit margin and 7.76% net profit margin provide a robust basis for evaluating profitability, as the company navigates the quarter with disciplined spending and an emphasis on profitable growth. Operating efficiency is supported by management’s recent guidance framework, which signals continued focus on expenses, thereby underpinning EBIT leverage; the current quarter EBIT estimate of $12.85 million, rising 137.96% year-over-year, speaks to improved cost control and scale benefits from the revenue base. Management’s preliminary indications for full-year performance point toward sustained revenue expansion and controlled operating expenses, which should help preserve gross margin integrity as product mix evolves. The last quarter’s adjusted EPS growth of 600% year-over-year indicates that revenue gains are translating into meaningful per-share earnings improvements, although the company is still pacing investments in development activities. For the current quarter, attention will be on the conversion of gross profit to operating income and whether the high-nineties gross margin percentile holds; even modest fluctuations in margin below historical averages would likely be offset by higher volumes and expense discipline if demand remains consistent. Given the strong quarter-on-quarter net profit acceleration of 60.80% previously, the market will focus on whether profit momentum carries into this quarter without undue dilution from selling, general, and administrative expense or development spend. Revenue elasticity to payer dynamics and product utilization will be closely watched, but the recent trajectory of $97.30 million last quarter and 30.00% year-over-year growth sets a constructive tone. Overall, the commercial portfolio appears aligned with consensus for double-digit top-line growth and incremental earnings, with margin resilience serving as a central pillar of the investment narrative this reporting cycle.

Joenja Franchise Outlook

The Joenja franchise remains a key growth contributor within Pharming Group N.V.’s portfolio, and it is the principal focus for incremental revenue contributions and long-term leverage. Management has signaled sustained revenue growth and advancement of the clinical pipeline in the year ahead, implying continued commercial development for Joenja even as the company addresses recent regulatory feedback on pediatric labeling. The U.S. Food and Drug Administration’s complete response letter regarding the pediatric application requested additional pediatric pharmacokinetic data to confirm dosing and clarification of an analytical method, which introduces a timing consideration but is addressable within regulatory pathways. In the nearer term, adult commercial use and geographic uptake remain primary revenue drivers for the Joenja franchise, with aggregate contributions reflected in the overall revenue base rather than disclosed as a separate line item. While this quarter does not carry a separate Joenja revenue number, the presence of strong total revenue growth at 30.00% year-over-year in the prior quarter suggests ongoing contribution from newer therapies. The current quarter estimate for total revenue at $105.19 million and adjusted EPS at $0.008, alongside the EBIT estimate of $12.85 million, implies that the franchise is contributing meaningfully without materially compressing margins, a favorable dynamic for near-term profitability while pediatric labeling matters are addressed. Management’s proactive engagement with regulators is important for medium-term growth, as pediatric expansion broadens the addressable patient base and enhances revenue durability. For this quarter, investors will watch for color on resubmission plans and timelines, with any clarity likely to shape expectations for portfolio mix and margin cadence later in the year. Even absent immediate pediatric approval, the franchise’s current commercial footprint continues to support the company’s top-line trajectory, and consensus implies confidence in the execution of adult market initiatives and operational follow-through.

Stock Price Drivers This Quarter

The primary stock price drivers this quarter include top-line delivery versus the $105.19 million revenue estimate, margin stability relative to the prior quarter’s 92.73% gross margin and 7.76% net margin, and adjusted EPS performance versus the $0.008 estimate. Earnings quality will be judged on the balance between revenue growth and expense discipline, especially in light of the recent guidance ranges for annual operating expenses, which signal management’s intent to maintain tight control over spending. EBIT performance will be a focal point for market participants, with the estimate of $12.85 million suggesting meaningful operating leverage; an outcome nearer last quarter’s $15.80 million would underscore upside execution on both revenue and costs. Another determinant will be management’s commentary on the full-year trajectory, including the interplay between commercial expansion and development priorities. The market has responded constructively to indications of 8% to 13% annual revenue growth, and investors will look for confirmation that the quarterly cadence aligns with that range. Regulatory updates regarding the pediatric resubmission process for Joenja may temporarily influence sentiment; however, the adult franchise and existing portfolio contributions are the principal near-term earnings drivers, and clarity on timelines could help reduce uncertainty in subsequent quarters. Finally, the interplay between margin conversion and EPS will be closely monitored, given the prior quarter’s 600% year-over-year increase in adjusted EPS to $0.01 and this quarter’s estimate of $0.008. If margins remain resilient and operating expenses track within management’s indicated ranges, the probability of meeting or exceeding EPS expectations improves. Share price reaction will likely be most sensitive to the combination of revenue outcome, EBIT delivery, and qualitative guidance on regulatory milestones that shape the revenue mix over the remainder of the year.

Analyst Opinions

The majority of institutional viewpoints gathered since January 1, 2026 lean bullish, supported by constructive full-year revenue indications and market expectations that reflect accelerating near-term growth. Consensus points to Pharming Group N.V. delivering sustained expansion in 2026, with aggregated expectations for annual revenue framed around guidance that indicates 8% to 13% growth; this backdrop aligns with the current quarter’s projected $105.19 million in revenue and 30.28% year-over-year growth. The positive tone stems from recent preliminary revenue commentary for 2025 suggesting approximately $376.00 million and disciplined operating expenses within communicated ranges, while the pediatric regulatory feedback is seen as a manageable timing factor rather than a fundamental shift in trajectory. On balance, the ratio of bullish to cautious views stands at roughly two to one in favor of the bullish camp, as institutions emphasize the earnings cadence and operating control demonstrated in the last quarter’s EBIT outperformance and EPS momentum. FactSet-linked consensus references for full-year revenue expectations have anchored a constructive stance, with investors extrapolating quarter-level trends to annual growth that is consistent with management’s indicated ranges. The core of the bullish argument is that the revenue base is expanding at a double-digit rate, margins have remained strong, and spending discipline supports operating leverage, all of which increase confidence in meeting or exceeding quarterly targets. Analysts in the bullish camp also highlight that the adult commercial footprint for the newer therapy is already translating into tangible contributions within total revenue, even as pediatric labeling requires additional steps. The emphasis is on continuity of execution rather than binary outcomes, with quarterly performance—revenue of $105.19 million, adjusted EPS of $0.008, and EBIT of $12.85 million—seen as consistent with an upward earnings trajectory. This perspective anticipates that strong gross margin positioning and carefully managed operating expenses will underpin both near-term EPS delivery and the company’s ability to reinvest in development where needed, reinforcing the positive stance on the quarter’s results preview.